menu search

Idor­sia notes po­ten­tial $440.8M Asia li­cens­ing deal to ex­tend cash run­way amid slow Qu­viviq sales

Swiss biopharma Idorsia gave out few details Tuesday about a potential $440.8 million (400 million CHF) deal with an unnamed company that would include licensing rights to some of Idorsia’s products … Read Full Story at source (may require registration) The post Idor­sia notes po­ten­tial $440.8M Asia li­cens­ing deal to ex­tend cash run­way amid slow Qu­viviq sales appeared first on ForexTV... Read More
Posted: Jun 6 2023, 12:00
Author Name: forextv
Views: 081331

Search within

Pages Search Results: